Research Library

Current medical research and literature may be overemphasizing the role that hospital volume plays in patient outcomes, according to a study co-authored by health economics fellow Vivian Ho.

High cancer drug prices reduce access to therapy, cause treatment abandonment and financial bankruptcies, as well as severe emotional and family distress.

This journal article examines the risks patients face in seeking experimental stem cell-based interventions from clinics outside the United States. The authors advocate for new public policies that encourage patients to remain in clinical trials in the U.S.

The 340B Drug Pricing Program, which allows uninsured or low-income patients to buy prescription drugs at discounted prices, is under attack.

Health care providers add multiple processes to the care of complex cancer patients, believing they prevent and/or ameliorate complications. However, the relationship between these processes, complication remediation, and expenditures is unknown.

In this commentary, the authors examine the roots of the United States’ reluctance to embrace universal health care, concluding that it "is neither sound nor ethical in a nation that promulgates fairness and equal opportunity" to deny coverage.

Genomic testing is a rapidly growing field, especially in cancer medicine, where it can be used to match patients to the most effective targeted treatment. In the past decade, we have seen rapid growth in the number of new genomic tests that are available. However, genomic testing is usually very expensive, raising the question of whether the testing is worth the cost.

Regionalization of care is associated with improved care and outcomes for patients with complex cancers.